The potential use of GH, IGF-1 modulators, or other agents that directly target the IGF-1 axis as therapeutic options for NAFLD remains an intriguing avenue for future exploration. The gene discussed is GH1; the disease is metabolic dysfunction-associated steatotic liver disease.